Clinical Trial Update: Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Polyphenon E in addition to Erlotinib for advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Polyphenon E (sinecatechin)

Snippet

Sponsor: Louisiana State University Health Sciences Center Shreveport | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED